XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Goodwill and Intangible Assets, Net
 6 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
In the second quarter of 2021, the Company implemented a new segment reporting structure which resulted in four reportable segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and RxTS. These reportable segments encompass all operating segments of the Company. This segment change prompted changes in multiple reporting units across the Company. As a result, goodwill included in impacted reporting units was reallocated using a relative fair value approach and assessed for impairment both before and after the reallocation.
The Company recorded a goodwill impairment charge of $69 million (pre-tax and after-tax) in the three and six months ended September 30, 2020 as the estimated fair value of the Europe Retail Pharmacy reporting unit was lower than its reassigned carrying value based on changes in the composition of the Europe Retail Pharmacy reporting unit within the International segment. This impairment charge is included under the caption, “Goodwill impairment charges” in the Condensed Consolidated Statements of Operations. At September 30, 2020, the reporting units in Europe had no remaining balance of goodwill and the remaining balance of goodwill in the International segment relates to one of its reporting units in Canada.
Refer to Financial Note 12, “Fair Value Measurements,” for more information.
Changes in the carrying amount of goodwill were as follows:
(In millions)U.S. PharmaceuticalInternationalMedical-Surgical SolutionsPrescription Technology SolutionsTotal
Balance, March 31, 2020$3,924 $1,443 $2,453 $1,540 $9,360 
Goodwill acquired— 1 — — 1 
Acquisition accounting, transfers and other adjustments— — — 2 2 
Impairment charges
— (69)— — (69)
Foreign currency translation adjustments, net39 81 — — 120 
Balance, September 30, 2020$3,963 $1,456 $2,453 $1,542 $9,414 
Information regarding intangible assets is as follows:
 September 30, 2020March 31, 2020
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships12$3,736 $(2,127)$1,609 $3,650 $(1,950)$1,700 
Service agreements10997 (506)491 994 (480)514 
Pharmacy licenses26502 (222)280 492 (232)260 
Trademarks and trade names12894 (314)580 808 (242)566 
Technology5147 (113)34 175 (111)64 
Other5253 (217)36 273 (221)52 
Total $6,529 $(3,499)$3,030 $6,392 $(3,236)$3,156 
Amortization expense of intangible assets was $106 million and $212 million during the three and six months ended September 30, 2020, respectively, and $118 million and $230 million during the three and six months ended September 30, 2019, respectively. Estimated amortization expense of these assets is as follows: $196 million, $367 million, $265 million, $248 million, and $245 million for the remainder of 2021 and each of the succeeding years through 2025 and $1.7 billion thereafter. All intangible assets were subject to amortization as of September 30, 2020 and March 31, 2020.